methyl (2S)-2-[[4-[[(2S)-2-amino-3-sulfanyl-propyl]amino]-2-phenyl-benzoyl]amino]-4-methylsulfanyl-butanoate

ID: ALA5193232

PubChem CID: 124514369

Max Phase: Preclinical

Molecular Formula: C22H29N3O3S2

Molecular Weight: 447.63

Names and Identifiers

Canonical SMILES:  COC(=O)[C@H](CCSC)NC(=O)c1ccc(NC[C@H](N)CS)cc1-c1ccccc1

Standard InChI:  InChI=1S/C22H29N3O3S2/c1-28-22(27)20(10-11-30-2)25-21(26)18-9-8-17(24-13-16(23)14-29)12-19(18)15-6-4-3-5-7-15/h3-9,12,16,20,24,29H,10-11,13-14,23H2,1-2H3,(H,25,26)/t16-,20-/m0/s1

Standard InChI Key:  GKFPROVOIQKYTO-JXFKEZNVSA-N

Molfile:  

 
     RDKit          2D

 30 31  0  0  0  0  0  0  0  0999 V2000
   -1.4279    1.0319    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7133    1.4442    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0013    1.0323    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0013    0.2072    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7115   -0.2045    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4279    0.2035    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7131    1.4449    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7134    2.2702    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4263    2.6809    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1411    2.2682    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1427    1.4471    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4309    1.0306    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7131   -0.2054    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4278    0.2072    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.1425   -0.2054    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7131   -1.0305    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.8571    0.2072    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5717   -0.2054    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.8571    1.0323    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.2864    0.2072    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1425   -1.0305    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8571   -1.4432    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8571   -2.2683    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    3.5717   -2.6809    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1425    1.4446    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8571    1.0319    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5718    1.4446    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2864    1.0319    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5718    2.2697    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2864    0.2068    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  1  0
  4  3  2  0
  5  4  1  0
  1  6  1  0
  6  5  2  0
  7  3  1  0
  8  7  2  0
  9  8  1  0
 10  9  2  0
 11 10  1  0
  7 12  1  0
 12 11  2  0
  4 13  1  0
 13 14  1  0
 14 15  1  0
 13 16  2  0
 15 17  1  0
 17 18  1  0
 17 19  2  0
 18 20  1  0
 15 21  1  6
 21 22  1  0
 22 23  1  0
 23 24  1  0
  1 25  1  0
 25 26  1  0
 26 27  1  0
 27 28  1  1
 27 29  1  0
 28 30  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5193232

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 447.63

Molecular Weight (Monoisotopic): 447.1650

AlogP: 3.05

#Rotatable Bonds: 11

Polar Surface Area: 93.45

Molecular Species: BASE

HBA: 7

HBD: 4

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 4

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 10.25

CX Basic pKa: 9.26

CX LogP: 2.47

CX LogD: 0.85

Aromatic Rings: 2

Heavy Atoms: 30

QED Weighted: 0.31

Np Likeness Score: -0.73

References

1. Korzeniecki C, Priefer R..  (2021)  Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.,  211  [PMID:33228976] [10.1016/j.ejmech.2020.113006]

Source

Source(1):

• Scientific Literature